Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases

February 14, 2025 12:11 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

HONG KONG, Feb. 14, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody targeting IL-4Rα and ST2. AK139 is under investigation for a number of indications, including respiratory and skin diseases.

AK139 is Akeso's first innovative bispecific antibody outside the field of oncology to enter clinical development.  It is also Akeso's seventh bispecific antibody to enter clinical development. As the world's first IL-4Rα/ST2 bispecific antibody to enter the clinic, AK139 simultaneously targets and blocks both the IL-4/IL-13 pathway (by binding to the IL-4Rα subunit shared by both IL-4 and IL-13 receptor complexes) and the IL-33/ST2-mediated inflammation pathway. Preclinical studies have demonstrated robust synergistic therapeutic effects between these targets. In preclinical studies, AK139 shows clinical potential compared to existing monotherapy drugs targeting these pathways.  AK139 is expected to advance the treatment of respiratory diseases, dermatological conditions, and other disorders where these inflammatory pathways play a critical role in disease pathogenesis. This first in class therapy is set to introduce a "dual-target era" in the treatment of these conditions, providing enhanced therapeutic options for patients with inadequate responses to current treatments.

Innovative Dual-Target Mechanism for Improved Therapeutic Potential

The IL-4, IL-13, and IL-33/ST2 pathways play a central role in the inflammatory processes underlying asthma, COPD, and other related conditions. AK139, as the first bispecific antibody targeting both IL-4Rα and ST2, offers a targeted approach to modulate these pathways. By binding to both IL-4Rα and ST2, AK139 blocks the key signals associated with IL-4, IL-13, and IL-33, addressing the complex inflammation signaling pathways in these related diseases.

  • IL-4Rα Pathway: IL-4 and IL-13 are primarily involved in immune responses mediated by T-helper 2 (Th2) cells. The Th2-mediated inflammatory pathways play a critical role in the pathogenesis and progression of respiratory diseases, skin conditions, and other related diseases. Research has shown that IL-4 and IL-13 share a common receptor, IL-4Rα. AK139 is highly specific in binding to IL-4Rα, blocking the interaction between IL-4Rα and IL-4 or IL-13, as well as inhibiting the downstream signaling pathways mediated by these interactions, and thus exerting therapeutic effects on these diseases.
  • IL-33/ST2 Pathway: Interleukin-33 (IL-33), acting as an alarm signal, binds to its specific receptor ST2, activating downstream signaling pathways that lead to inflammation in multiple human biological systems, including the respiratory, cardiovascular, and musculoskeletal systems. IL-33 plays a key role in both type 2 and non-type 2 inflammatory responses. Studies have shown that the expression levels of IL-33 and its receptor ST2 are significantly elevated in inflammatory diseases such as respiratory and skin conditions, where they serve as important mediators of disease response. AK139 specifically binds to ST2, inhibiting the inflammatory response mediated by IL-33.

Preclinical studies have demonstrated that AK139 showcases strong dual-specific antigen-binding activity and promising pharmacological effects in both in-vitro and in-vivo. The antibody has shown remarkable synergy between the targets, significantly outperforming single-target antibodies targeting IL-4 or ST2 in key measures.  These key measures include the inhibition of inflammatory cytokine release and the reduction of tissue infiltration by inflammatory cells. Additionally, preclinical toxicology studies showed that AK139 presents a favorable safety profile.

Based on the pre-clinical data so far, AK139 has the potential to become a breakthrough therapy for respiratory and dermatological diseases.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.